Allergy Therapeutics agrees new debt funding
Published: 03:26 23 Feb 2026 EST
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has put fresh debt funding in place after agreeing a new £40m committed senior secured term loan from Hayfin, designed to replace the £20m uncommitted incremental option embedded in its 2024 financing package.
The AIM-listed allergy immunotherapy group said it intends to fully draw the new facility, which it expects will provide working capital for at least the next 12 months, giving it breathing room to pursue a potential Hong Kong Stock Exchange listing and support growth following the Grassmuno launch in Germany.
The 2026 facility is priced at a variable rate of SONIA plus 9.5% per annum and is subject to an upfront arrangement fee. If a Hong Kong listing completes by 31 December 2026, the company said repayment on amounts drawn under the facilities would be pushed out to 20 February 2031; otherwise, repayment would fall due on 16 October 2029.
